Skip to Content for 1998 Annual Report Menu for 1998 Annual Report About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu Careers Menu
Banner Image

1998 Annual Report

In Business for Life

The ultimate goal of Genentech's efforts is to improve or extend people's lives. In 1998, Genentech achieved that goal again with the approval of its new monoclonal antibody medicine, Herceptin, for treating certain patients with metastatic breast cancer. Pictured on the front of Genentech's Founders Research Center, Shirley Michaelsen is one of many breast cancer patients to benefit from Herceptin.

Topics

Financial Highlights (PDF/38K)
Business Events (PDF/339K)
Print Version (PDF/312K)
Letter to Stockholders (PDF/549K)
Print Version (PDF/414K)

Leading into a New Millennium
Genentech's Strategy (p. 10) (PDF/3,333K)
Print Version (PDF/3,881K)

Where Discovery is Delivered
Print Version (PDF/2,775K)

Innovate to Live, Live to Innovate
Product Discovery (p. 18) (PDF/255K)
Print Version (PDF/691K)

Pipeline as Lifeline
Product Development Pipeline (p. 20) (PDF/345K)
Print Version (PDF/2,775K)

  

Investing in the Heart of Our Success
Genentech People (p. 24) (PDF/1,748K)
Print Version (PDF/1,746K)
The Power of Partners (PDF/49K)
Print Version (PDF/46K)

In Business for Results
Improving Our Financial Returns (p. 28) (PDF/339K)

Print Version (PDF/312K)

Financial Section (PDF/267K)

Stockholder Information (PDF/46K)

Board of Directors, Officers, Staff Scientists and Distinguished Engineer (PDF/32K)

To open PDF documents, please download the latest version of Adobe Acrobat Reader, a free download.